CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

March 1, 2021

PHILADELPHIAMarch 1, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA’s total capital raised to date to nearly $121 million. Click here for more information.